Double‐blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase A inhibitors, pirlindole and moclobemide, in the treatment of depression

Tanghe, A; Geerts, S.; Dorpe, J. Van; Brichard, Bénédicte; Bruhwyler, Jacques; Géczy, Joseph

doi:10.1111/j.1600-0447.1997.tb09918.x

Cited by 18 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are many factors that can cause xerostomia [15]. The main reason is taking medication, especially from the anticholinergic [16,17,18], sympathomimetic [19,20,21,22] and antihypertensive [23] groups. Some opioids, benzodiazepines [24,25] and anti-migraine agents [26] may also contribute to salivary disorders.…”

Section: Xerostomia: Etiology Of Salivary Glands Dysfunctionsmentioning

confidence: 99%

Artificial Saliva: Challenges and Future Perspectives for the Treatment of Xerostomia

Łysik

Niemirowicz-Laskowska

Bucki

et al. 2019

IJMS

View full text Add to dashboard Cite

The chronic sensation of a dry mouth is a disease condition called xerostomia and affects a large part of the population. Xerostomia is associated with decreased secretion, or more often, qualitative changes in saliva proteins and immunoglobulin concentrations that develop as a result of salivary gland dysfunction. Several reasons causing dry mouth were described, and usually, they include taking medications, diseases or radiotherapy. In some situations, when it is difficult to use salivary stimulants or salivary gland damage is irreversible, the only option might seem to be saliva substitutes. The paper presents the most important aspects considering saliva preparations. The rheological and lubricating properties and the reconstruction of the complex saliva structure has been the main purpose of research. The biological properties of saliva preparations were also widely discussed. As part of the work, the antimicrobial effect of three commercial saliva preparations was tested. Finally, inadequate antimicrobial properties against the strains isolated from the oral cavity were demonstrated. The development of salivary substitutes, in particular, the improvement of antimicrobial properties, can be achieved using nanotechnology, including drug delivery systems containing nanocarriers.

show abstract

Section: Xerostomia: Etiology Of Salivary Glands Dysfunctionsmentioning

confidence: 99%

Artificial Saliva: Challenges and Future Perspectives for the Treatment of Xerostomia

Łysik

Niemirowicz-Laskowska

Bucki

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…It has also been shown to be effective in the treatment of dysthymia; 57% of the patients responded after 8 weeks of treatment (Versiani et al, 1997). Side effects include dry mouth and tachycardia, but the drug appears to be well tolerated in the majority of patients (Tanghe et al, 1997).…”

Section: Moclobemidementioning

confidence: 99%

Emerging antidepressants to treat major depressive disorder

Block

Nemeroff

2014

Asian Journal of Psychiatry

View full text Add to dashboard Cite

“…Either of the two drugs produced highly significant improvements in HAM-D, the Hamilton Anxiety Rating Scale and the MADRS from day 7 to day 42. After 42 days of treatment, an improvement of ³50% in the HAM-D score was noted in 67 and 80% of patients in the moclobemide and pirlindole group, respectively (230).…”

Section: Other Antidepressants Including Mao-inhibitorsmentioning

confidence: 99%

Moclobemide: Therapeutic Use and Clinical Studies

Bonnet¹

2003

CNS Drug Reviews

205

100

View full text Add to dashboard Cite

Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) and has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively studied in anxiety disorders. Nearly all meta-analyses and most comparative studies indicated that in the acute management of depression this drug is more efficacious than placebo and as efficacious as tricyclic (or some heterocyclic) antidepressants or selective serotonin reuptake inhibitors (SSRIs). There is a growing evidence that moclobemide is not inferior to other antidepressants in the treatment of subtypes of depression, such as dysthymia, endogenous (unipolar and bipolar), reactive, atypical, agitated, and retarded depression as with other antidepressants limited evidence suggests that moclobemide has consistent long-term efficacy. However, more controlled studies addressing this issue are needed. For patients with bipolar depression the risk of developing mania seems to be not higher with moclobemide than with other antidepressants. The effective therapeutic dose range for moclobemide in most acute phase trials was 300 to 600 mg, divided in 2 to 3 doses. While one controlled trial and one long-term open-label study found moclobemide to be efficacious in social phobia, three controlled trials subsequently revealed either no effect or less robust effects with the tendency of higher doses (600 -900 mg /d) to be more efficacious. Two comparative trials demonstrated moclobemide to be as efficacious as fluoxetine or clomipramine in patients suffering from panic disorder. Placebocontrolled trials in this indication are, however, still lacking.A relationship between the plasma concentration of moclobemide and its therapeutic efficacy is not apparent but a positive correlation with adverse events has been found. Dizziness, nausea and insomnia occurred more frequently on moclobemide than on placebo. Due to negligible anticholinergic and antihistaminic actions, moclobemide has been better tolerated than tri-or heterocyclic antidepressants. Gastrointestinal side effects and, espe-97

show abstract

Double‐blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase A inhibitors, pirlindole and moclobemide, in the treatment of depression

Cited by 18 publications

References 18 publications

Artificial Saliva: Challenges and Future Perspectives for the Treatment of Xerostomia

Artificial Saliva: Challenges and Future Perspectives for the Treatment of Xerostomia

Emerging antidepressants to treat major depressive disorder

Moclobemide: Therapeutic Use and Clinical Studies

Contact Info

Product

Resources

About